MCAL Therapeutics Treatments of ophthalmic diseases Website Operator of a biotechnology company intended to treat ophthalmic diseases. The company advances ophthalmology discoveries from a dry eye platform, enabling healthcare providers to cure their patients. Domain Topical Ophthamology First Partnered Seed Current Status Active Investors Tom Mather Leadership Thomas Gadek Ph.D, CEO HQ Park City, UT In the News View all December 14, 2023 Novel Lipids of the Rabbit Harderian Gland Improve Tear Stability in an Animal Model of Dry Eye Disease Read
December 14, 2023 Novel Lipids of the Rabbit Harderian Gland Improve Tear Stability in an Animal Model of Dry Eye Disease Read